PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Brimonidine tartrate - Glaucoma / ocular hypertension
PAD Profile : Brimonidine tartrate - Glaucoma / ocular hypertension Important
Keywords :
Intra-ocular pressure
Brand Names Include :
Alphagan
Important Information :
Prescribe generically.
Initiation by specialist team before transfer of prescribing to primary care
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Latanoprost
- Bimatoprost
- Timolol
- Dorzolamide and timolol
- Brinzolamide
- Dorzolamide
- Latanoprost and timolol
- Acetazolamide
- Timolol and bimatoprost
- Timolol and brimonidine
- Brinzolamide/brimonidine
- Brinzolamide and timolol
- Tafluprost
- Travoprost
- Timolol and travoprost
- Pilocarpine hydrochloride
- Betaxolol
- Levobunolol hydrochloride
- Apraclonidine
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
02 October 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.
22 July 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Primary care prescribers do not have the necessary equipment or skills to perform ocular pressure readings to make a diagnosis. The APC recomments that this product, when used for treatment of glaucoma, should be considered as BLUE.
Note; the branded product (Alphagan) was considered BLACK at the PCN in May 2017.
Associated BNF Codes
11. Eye
11.06.00. Treatment of glaucoma